Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q2 EPS of $1.79, $0.09 better than the analyst estimate of $1.70. Revenue for the quarter came in at $119.2 million versus the consensus estimate of $122.3 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.